Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JIN SUN L BITAR

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1477940161
CMS profile
5678034
Location
LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$3,705.55

105 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,655.55 104
Consulting Fee $1,050.00 1

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JIN SUN L BITAR

NPI 1477940161 · CMS profile ID 5678034

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1477940161?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JIN SUN L BITAR, NPI 1477940161, CMS profile ID 5678034. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1477940161?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JIN SUN L BITAR, NPI 1477940161, CMS profile ID 5678034. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1477940161?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JIN SUN L BITAR, NPI 1477940161, CMS profile ID 5678034, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1477940161?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

105 matching records · $3,705.55 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 105 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–105 of 105.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Blueprint Medicines Corporation $23.2501/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958937467 CMS
AstraZeneca Pharmaceuticals LP $20.0001/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915008737 CMS
EISAI INC. $23.1301/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908047219 CMS
Genentech USA, Inc. $23.7001/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950804765 CMS
Incyte Corporation $22.0001/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942977351 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,200.21 39
PY2020 $190.01 10
PY2021 $1,807.67 60
PY2022 $3,705.55 105
PY2023 $249.29 3
PY2024 $2,723.42 5
PY2025 $15.81 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $480,931.04 36
PY2024 Principal investigator $37,600.00 11

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

36 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $70,024.43 12/31/2025 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastatic Breast Cancer After Progression on Previous E No dispute reported 06/30/2026 1232935165
Principal investigator 1 PFIZER INC. $57,300.60 12/09/2025 Covered Recipient Teaching Hospital
CEDARS-SINAI MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228712328
Principal investigator 1 PFIZER INC. $7.50 12/09/2025 Covered Recipient Teaching Hospital
CEDARS-SINAI MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228712526
Principal investigator 1 Merck Sharp & Dohme LLC $64,980.90 12/03/2025 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastatic Breast Cancer After Progression on Previous E No dispute reported 06/30/2026 1232935163
Principal investigator 1 PFIZER INC. $15.00 11/24/2025 Covered Recipient Teaching Hospital
CEDARS-SINAI MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228712528
Principal investigator 1 PFIZER INC. $500.00 11/19/2025 Covered Recipient Teaching Hospital
CEDARS-SINAI MEDICAL CENTER
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721923
Principal investigator 1 PFIZER INC. $500.00 11/19/2025 Covered Recipient Teaching Hospital
CEDARS-SINAI MEDICAL CENTER
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722041
Principal investigator 1 PFIZER INC. $15.00 11/18/2025 Covered Recipient Teaching Hospital
CEDARS-SINAI MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228712400
Principal investigator 1 PFIZER INC. $7.50 11/10/2025 Covered Recipient Teaching Hospital
CEDARS-SINAI MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228712330
Principal investigator 1 PFIZER INC. $57,300.60 11/10/2025 Covered Recipient Teaching Hospital
CEDARS-SINAI MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228712460
Principal investigator 1 PFIZER INC. $500.00 10/17/2025 Covered Recipient Teaching Hospital
CEDARS-SINAI MEDICAL CENTER
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721853
Principal investigator 1 PFIZER INC. $500.00 10/17/2025 Covered Recipient Teaching Hospital
CEDARS-SINAI MEDICAL CENTER
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721971
Principal investigator 1 PFIZER INC. $500.00 10/17/2025 Covered Recipient Teaching Hospital
CEDARS-SINAI MEDICAL CENTER
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721973
Principal investigator 1 PFIZER INC. $500.00 10/17/2025 Covered Recipient Teaching Hospital
CEDARS-SINAI MEDICAL CENTER
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722037
Principal investigator 1 PFIZER INC. $500.00 10/17/2025 Covered Recipient Teaching Hospital
CEDARS-SINAI MEDICAL CENTER
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722039
Principal investigator 1 Genentech, Inc. $3,258.31 10/14/2025 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
Chemo trastuzumab vs chemo trastuzumab pertuzumab No dispute reported 06/30/2026 1211542062
Principal investigator 1 PFIZER INC. $500.00 10/02/2025 Covered Recipient Teaching Hospital
CEDARS-SINAI MEDICAL CENTER
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721851
Principal investigator 1 PFIZER INC. $500.00 10/02/2025 Covered Recipient Teaching Hospital
CEDARS-SINAI MEDICAL CENTER
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721855
Principal investigator 1 PFIZER INC. $500.00 10/02/2025 Covered Recipient Teaching Hospital
CEDARS-SINAI MEDICAL CENTER
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228721921
Principal investigator 1 Genentech, Inc. $1,062.50 10/01/2025 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
Chemo trastuzumab vs chemo trastuzumab pertuzumab No dispute reported 06/30/2026 1211542058
Principal investigator 1 PFIZER INC. $13,123.52 09/16/2025 Covered Recipient Teaching Hospital
CEDARS-SINAI MEDICAL CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1228759085
Principal investigator 1 Genentech, Inc. $562.50 09/03/2025 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
Chemo trastuzumab vs chemo trastuzumab pertuzumab No dispute reported 06/30/2026 1211542054
Principal investigator 1 Merck Sharp & Dohme LLC $88,410.24 08/31/2025 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastatic Breast Cancer After Progression on Previous E No dispute reported 06/30/2026 1232935389
Principal investigator 1 PFIZER INC. $4,850.00 08/08/2025 Covered Recipient Teaching Hospital
CEDARS-SINAI MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228766947
Principal investigator 1 AstraZeneca UK Limited $10,292.00 08/01/2025 Covered Recipient Teaching Hospital
Cedars-sinai Medical Center
ROSY-O Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Olaparib and Are Judged by the Investigator to Clinically Benefit From Continued Treatment No dispute reported 06/30/2026 1185539525
Principal investigator 1 PFIZER INC. $45,792.00 06/26/2025 Covered Recipient Teaching Hospital
CEDARS-SINAI MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228777164
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Covered Recipient Teaching Hospital
CEDARS-SINAI MEDICAL CENTER
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228786825
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Covered Recipient Teaching Hospital
CEDARS-SINAI MEDICAL CENTER
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228787165
Principal investigator 1 PFIZER INC. $600.00 06/23/2025 Covered Recipient Teaching Hospital
CEDARS-SINAI MEDICAL CENTER
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228789055
Principal investigator 1 PFIZER INC. $7,437.00 05/06/2025 Covered Recipient Teaching Hospital
CEDARS-SINAI MEDICAL CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1228782078
Principal investigator 1 PFIZER INC. $500.00 04/29/2025 Covered Recipient Teaching Hospital
CEDARS-SINAI MEDICAL CENTER
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228786598
Principal investigator 1 PFIZER INC. $500.00 04/29/2025 Covered Recipient Teaching Hospital
CEDARS-SINAI MEDICAL CENTER
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228786690
Principal investigator 1 PFIZER INC. $500.00 04/29/2025 Covered Recipient Teaching Hospital
CEDARS-SINAI MEDICAL CENTER
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228789237
Principal investigator 1 PFIZER INC. $500.00 03/12/2025 Covered Recipient Teaching Hospital
CEDARS-SINAI MEDICAL CENTER
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228788431
Principal investigator 1 PFIZER INC. $500.00 01/30/2025 Covered Recipient Teaching Hospital
CEDARS-SINAI MEDICAL CENTER
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228787161
Principal investigator 1 AstraZeneca UK Limited $47,391.44 01/28/2025 Covered Recipient Teaching Hospital
Cedars-sinai Medical Center
CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease No dispute reported 06/30/2026 1185539523